Australian enalapril hypertension study

Introduction

Open label, randomized trial, supported by the Australian government & the makers of enalapril.

6083 hypertensive patients, age 65-84

almost all patients white

patients healthy:

• few patients had diabetes or known coronary artery disease

mean blood pressure 168/91

ACE inhibitor or diuretic as initial therapy

• Enalapril & HCTZ were recommended, but were not mandatory
• Additional medication administered with monotherapy was inadequate

4 years of follow-up

Results:

• blood pressure reduction identical in both groups
• combined endpoint of cardiovascular event or all-cause mortality 5.6% in ACE inhibitor group, 6.0% in diuretic group (p=0.05)
• ACE inhibitor group had significantly lower rate of myocardial infarction, but not stroke or all-cause mortality

More general terms

• hypertension clinical trials